top of page
  • ODI Pharma

ODI Pharma AB postpones publication of interim report and annual report until November 25, 2022

ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2022/2023 and the annual report for the fiscal year 2021/2022 would be published on November 24, 2022. Instead, the interim report and the annual report will be published on November 25, 2022, three weeks before the Annual General Meeting on December 16, 2022.

For more information, please contact:

Derek Simmross, CEO, ODI Pharma AB


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external international party in order to create flexibility in the operations

Original on Transparent.png
bottom of page